Academic Journal
LBA58 Sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated non-squamous non-small cell lung cancer (EGFRm nsqNSCLC) who progressed on EGFR tyrosine-kinase inhibitors (TKIs) therapy: Second interim analysis of phase III ORIENT-31 study
| العنوان: | LBA58 Sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated non-squamous non-small cell lung cancer (EGFRm nsqNSCLC) who progressed on EGFR tyrosine-kinase inhibitors (TKIs) therapy: Second interim analysis of phase III ORIENT-31 study |
|---|---|
| المؤلفون: | Lu, S., Wu, L., Jian, H., Cheng, Y., Wang, Q., Fang, J., Wang, Z., Hu, Y., Han, L., Sun, M., Miao, L., Ding, C., Cui, J., Wang, K., Li, B., Li, X., Ye, F., Liu, A., Pan, Y., Cang, S. |
| المصدر: | Annals of Oncology ; volume 33, page S1424 ; ISSN 0923-7534 |
| بيانات النشر: | Elsevier BV |
| سنة النشر: | 2022 |
| المجموعة: | ScienceDirect (Elsevier - Open Access Articles via Crossref) |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1016/j.annonc.2022.08.060 |
| الاتاحة: | http://dx.doi.org/10.1016/j.annonc.2022.08.060 https://api.elsevier.com/content/article/PII:S0923753422039382?httpAccept=text/xml https://api.elsevier.com/content/article/PII:S0923753422039382?httpAccept=text/plain |
| Rights: | https://www.elsevier.com/tdm/userlicense/1.0/ ; http://www.elsevier.com/open-access/userlicense/1.0/ |
| رقم الانضمام: | edsbas.99BC8EC9 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.annonc.2022.08.060 |
|---|